 |
|
| • October 13 |
|
ONCOLYS BIOPHARMA SIGN STRATEGIC ALLIANCE AND LICENSE AGREEMENT WITH ASTELLAS PHARMA TO DEVELOP AND COMMERCIALIZE YM753 HDAC INHIBITOR DRUG |
|
 |
|
|
| • February 10 |
|
Oncolys BioPharma Inc. Presented A Result of Phase Ia Clinical Study for Festinavir™ (OBP-601), A Novel Anti-HIV Drug, at 16th CROI Held in Montreal, Canada. |
|
|
|
|
| • February 4 |
|
Oncolys BioPharma Inc. commenced a repeated dose phase Ib clinical study for Festinavir™ (OBP-601), a novel anti-HIV drug, in HIV infected patients. |
|
|
|
|
| |
| • January 21 |
|
ONCOLYS BIOPHARMA AND SYSMEX CORPORATON SIGN COLLABORATIVE RESEARCH AND DEVELOPMENT AGREEMENT FOR IN-VITRO CANCER CIRCULATING TUMOR CELL DIAGNOSTIC AGENT |
|
|
|
|
|
 |
|
| • May 29 |
|
ONCOLYS BIOPHARMA DISCLOSED THE INTERIM CLINICAL RESULT OF A PHASE I CLINICAL TRIAL OF TELOMELYSINTM (OBP-301) AT ASCO 2008 (AMERICAN SOCIETY OF CLINICAL ONCOLOGY), IN CHICAGO |
|
|
|
|
| • April 15 |
|
Festinavir (OBP-601) successfully passed the US FDA IND review process and is ready to initiate Ph-I clinical trial in the United States. |
|
|
|
|
| • March 24 |
|
Oncolys BioPharma, Inc. Raises $8.2Million (JPY 815,980,000) In Equity Private Placements |
|
|
|
|
| • March 18 |
|
Oncolys BioPharma Inc. submitted an IND for FESTINAVIR® (OBP-601),a novel anti-HIV drug, to the FDA to gain permission to initiate Ph-Iclinical trial in human. |
|
|
|
|
| • March 13 |
|
ONCOLYS BIOPHARMA AND TACERE THERAPEUTICS SIGN STRATEGIC ALLIANCE AND LICENSE AGREEMENT TO DEVELOP AND COMMERCIALIZE RNAi HEPATITIS C DRUG |
|
|
|
|
| • March 6 |
|
Oncolys BioPharma and Medigen Biotechnology Enters Strategic Alliance and License Agreement to Develop and Commercialize Telomelysin® (OBP-301) for a Potential New Treatment for Solid Tumors |
|
|
|
|
|
 |
|
|
| • November 5 |
|
Oncolys BioPharma Opens New Research Center in Kobe |
|
|
|
|
|
| • June 21 |
|
ONCOLYS BIOPHARMA AND TACERE THERAPEUTICS FORM STRATEGIC ALLIANCE TO DEVELOP RNAi HEPATITIS C DRUG |
|
|
|
|
|
 |
|
|
| • November 2 |
|
Oncolys BioPharma, Inc. Raises $23.8 Million (JPY 2.6 Billion) In Equity Private Placements |
|
|
|
|
| • October 31 |
|
Oncolys BioPharma Announces That The First Patient Is in The Phase I Clinical Study of Telomelysin® for Solid Tumors in US |
|
|
|
|
| • October 11 |
|
Oncolys BioPharma Opened Own Research Center |
|
|
|
|
| • August 25 |
|
Japan’s First Anti-cancer Adenovirus Is Now GO for Clinical Studies in US |
|
|
|
|
|
|
|
